The Balamuthia mandrillaris amoeba got into her upper nasal cavity and then into her bloodstream, eventually reaching her brain, according to the study published in the December issue of the International Journal of Infectious Diseases.
During 2004 to 2016, 82 percent of all tickborne disease reports were Lyme disease
These tests are intended to screen samples from individual human donors, including volunteers who give whole blood and blood components, as well as living organ and tissue donors.
Miltefosine is an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. It is already approved to treat visceral, mucosal and cutaneous leishmaniasis in patients aged ≥12 years; it is the first oral treatment for this rare tropical parasitic disease.
“Less than 1% with the infection are receiving treatment for Chagas disease,” said Dr. Sheba Meymandi, Director of the Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center.
Profounda announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for Impavido (miltefosine) to treat primary amebic meningoencephalitis (PAM), also known as the “Brain Eating Amoeba”.
Profounda announced the launch of Impavido (miltefosine) for the treatment of visceral, mucosal, and cutaneous leishmaniasis in patients aged ≥12 years.
Imprimis Pharmaceuticals announced that it has made available a compounded formulation of pyrimethamine and leucovorin as a lower-cost alternative to Daraprim (pyrimethamine; Turing Pharmaceuticals).
Turing Pharmaceuticals has agreed to reduce the cost of its drug Daraprim (pyrimethamine) after receiving significant criticism due to a sudden increase in the price of the medication.
For patients with established Chagas’ cardiomyopathy, benznidazole may reduce serum parasite detection.
